Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 4 |
List of Tables | 5 | 1 |
List of Figures | 5 | 1 |
Chiesi Farmaceutici SpA Snapshot | 6 | 1 |
Chiesi Farmaceutici SpA Overview | 6 | 1 |
Key Facts | 6 | 1 |
Chiesi Farmaceutici SpA Research and Development Overview | 7 | 3 |
Key Therapeutic Areas | 7 | 3 |
Chiesi Farmaceutici SpA Pipeline Review | 10 | 7 |
Pipeline Products by Stage of Development | 10 | 1 |
Pipeline Products Monotherapy | 11 | 1 |
Pipeline Products Combination Treatment Modalities | 12 | 1 |
Pipeline Products Partnered Products | 13 | 1 |
Partnered Products/Combination Treatment Modalities | 14 | 1 |
Pipeline Products Out-Licensed Products | 15 | 1 |
Out-Licensed Products/Combination Treatment Modalities | 16 | 1 |
Chiesi Farmaceutici SpA Pipeline Products Glance | 17 | 5 |
Chiesi Farmaceutici SpA Late Stage Pipeline Products | 17 | 1 |
Phase III Products/Combination Treatment Modalities | 17 | 1 |
Chiesi Farmaceutici SpA Clinical Stage Pipeline Products | 18 | 1 |
Phase II Products/Combination Treatment Modalities | 18 | 1 |
Phase I Products/Combination Treatment Modalities | 19 | 1 |
Chiesi Farmaceutici SpA Early Stage Pipeline Products | 20 | 1 |
Preclinical Products/Combination Treatment Modalities | 20 | 1 |
Chiesi Farmaceutici SpA - Unknown Stage Pipeline Products | 21 | 1 |
Unknown Products/Combination Treatment Modalities | 21 | 1 |
Chiesi Farmaceutici SpA Drug Profiles | 22 | 23 |
(beclomethasone dipropionate + formoterol fumarate + glycopyrrolate) Drug Profile | 22 | 3 |
budesonide Drug Profile | 25 | 1 |
CHF-5633 Drug Profile | 26 | 1 |
CHF-6001 Drug Profile | 27 | 2 |
CHF-6297 Drug Profile | 29 | 1 |
CPD-15 Drug Profile | 30 | 1 |
Drugs for Bronchopulmonary Dysplasia Drug Profile | 31 | 1 |
glycopyrrolate Drug Profile | 32 | 2 |
melatonin Drug Profile | 34 | 1 |
meropenem Drug Profile | 35 | 1 |
Recombinant Enzymes for Rare Diseases Drug Profile | 36 | 1 |
Recombinant Protein for Neonatal Respiratory Distress Syndrome Drug Profile | 37 | 1 |
Recombinant Protein to Target NGF for Undisclosed Indication Drug Profile | 38 | 1 |
Small Molecule to Inhibit Neutrophil Elastase for Respiratory Diseases Drug Profile | 39 | 1 |
Small Molecule to Target Beta 2 Adrenergic Receptor and Muscarinic Acetylcholine Receptor M3 for Asthma and COPD Drug Profile | 40 | 1 |
Small Molecules for Neonatal Abstinence Syndrome Drug Profile | 41 | 1 |
TRP-601 Drug Profile | 42 | 1 |
velmanase alfa Drug Profile | 43 | 2 |
Chiesi Farmaceutici SpA Pipeline Analysis | 45 | 6 |
Chiesi Farmaceutici SpA Pipeline Products by Target | 45 | 2 |
Chiesi Farmaceutici SpA Pipeline Products by Route of Administration | 47 | 1 |
Chiesi Farmaceutici SpA Pipeline Products by Molecule Type | 48 | 1 |
Chiesi Farmaceutici SpA Pipeline Products by Mechanism of Action | 49 | 2 |
Chiesi Farmaceutici SpA Dormant Projects | 51 | 1 |
Chiesi Farmaceutici SpA Discontinued Pipeline Products | 52 | 2 |
Discontinued Pipeline Product Profiles | 53 | 1 |
beclomethasone dipropionate SR | 53 | 1 |
carmoterol | 53 | 1 |
indantadol | 53 | 1 |
Porphozym | 53 | 1 |
Chiesi Farmaceutici SpA Company Statement | 54 | 2 |
Chiesi Farmaceutici SpA Locations And Subsidiaries | 56 | 4 |
Head Office | 56 | 1 |
Other Locations &Subsidiaries | 57 | 3 |
Appendix | 60 | 2 |
Methodology | 60 | 1 |
Coverage | 60 | 1 |
Secondary Research | 60 | 1 |
Primary Research | 60 | 1 |
Expert Panel Validation | 60 | 1 |
Contact Us | 60 | 1 |
Disclaimer | 61 | 1 |